{"entity":{"id":"nct06682988","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","aka":[],"tldr":"A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, now recruiting.","summary":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine is a phase 2 interventional study registered as NCT06682988 by AbbVie, with 110 participants planned, started 2025-05-28 and due to reach its primary completion in 2026-07. Interventions recorded: Mirvetuximab Soravtansine. Conditions listed: Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06682988","url":"https://clinicaltrials.gov/study/NCT06682988"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","platinum-resistant-ovarian-cancer"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["mirvetuximab-soravtansine"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06682988","phase":"2","setting":"A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment","sponsor":"AbbVie","participation":[{"nct":"NCT06682988","source":"https://clinicaltrials.gov/study/NCT06682988","fetchedAt":"2026-10-07T16:54:54.827Z","studySha256":"29307c2b5526bda398531e24f22030391f6b59ccf6a22588b121a9d3ccfda823","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-26","leadSponsor":"AbbVie","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":110,"enrolmentType":"ESTIMATED","siteCount":52,"recruitingSiteCount":52,"countries":["Australia","Belgium","France","Poland","South Korea","Spain","United Kingdom","United States"]}],"started":"2025-05-28","startedType":"actual","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06682988/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}